Revelation Biosciences, Inc. (REVB) Balance Sheet

The contraction in equity base suggests that the company is consuming its capital at a rate that outpaces its ability to generate value through clinical milestones. Investors should monitor whether this trajectory forces management into increasingly dilutive financing arrangements to sustain basic operations.

While the current ratio of 5.41 appears superficially healthy, it is largely a function of the company's limited liability profile rather than operational strength. The rapid burn of cash reserves suggests that the company's liquidity is highly sensitive to the timing of future capital raises.

The deepening deficit underscores the speculative nature of the business model, where equity value is entirely dependent on future clinical success rather than current earnings power. This structure implies that shareholders are effectively funding a high-risk R&D project with little protection from the underlying capital erosion.